In the pursuit of market outperformance, investors navigate the landscape of stock selection. The right picks can play a pivotal role in enhancing your wealth.
In the latest session, Diebold Nixdorf Inc (NYSE: DBD) closed at $59.0 up 2.16% from its previous closing price of $57.75. In other words, the price has increased by $2.16 from its previous closing price. On the day, 0.27 million shares were traded. DBD stock price reached its highest trading level at $59.36 during the session, while it also had its lowest trading level at $58.015.
Ratios:
For a deeper understanding of Diebold Nixdorf Inc’s stock, let’s take a closer look at its various ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 6.70 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 12.95. For the most recent quarter (mrq), Quick Ratio is recorded 0.91 and its Current Ratio is at 1.35. In the meantime, Its Debt-to-Equity ratio is 1.07 whereas as Long-Term Debt/Eq ratio is at 1.02.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Wedbush on May 03, 2024, Upgraded its rating to Outperform and sets its target price to $50 from $40 previously.
On November 10, 2023, DA Davidson Upgraded its rating to Buy which previously was Neutral and also upped its target price recommendation from $25 to $29.
On August 15, 2023, DA Davidson started tracking the stock assigning a Neutral rating and target price of $25.DA Davidson initiated its Neutral rating on August 15, 2023, with a $25 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on May 09 ’25 when Baur Frank Tobias bought 700 shares for $46.12 per share. The transaction valued at 32,284 led to the insider holds 38,572 shares of the business.
PEARLMAN EMANUEL R bought 16,055 shares of DBD for $742,405 on May 09 ’25. On Feb 28 ’25, another insider, PEARLMAN EMANUEL R, who serves as the Director of the company, sold 2,000 shares for $43.68 each. As a result, the insider received 87,360 and left with 40,000 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, DBD now has a Market Capitalization of 2198569984 and an Enterprise Value of 2812218624. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.59 while its Price-to-Book (P/B) ratio in mrq is 2.25. Its current Enterprise Value per Revenue stands at 0.761 whereas that against EBITDA is 6.801.
Stock Price History:
The Beta on a monthly basis for DBD is 1.69, which has changed by 0.49215984 over the last 52 weeks, in comparison to a change of 0.12792087 over the same period for the S&P500. Over the past 52 weeks, DBD has reached a high of $58.04, while it has fallen to a 52-week low of $34.38. The 50-Day Moving Average of the stock is 19.64%, while the 200-Day Moving Average is calculated to be 30.29%.
Shares Statistics:
For the past three months, DBD has traded an average of 200.90K shares per day and 396810 over the past ten days. A total of 37.46M shares are outstanding, with a floating share count of 36.58M. Insiders hold about 1.84% of the company’s shares, while institutions hold 120.86% stake in the company. Shares short for DBD as of 1749772800 were 885857 with a Short Ratio of 4.41, compared to 1747267200 on 980104. Therefore, it implies a Short% of Shares Outstanding of 885857 and a Short% of Float of 4.61.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
